Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Dermatology

Diagnosis and Risk Stratification: Understanding the Criteria

At a Glance

Neurocutaneous melanocytosis (NCM) is diagnosed by assessing the risk of pigment cells in the central nervous system. Key risk factors include a Giant Projected Adult Size (PAS) over 40 cm, having more than 20 satellite moles, and having a primary birthmark on the head, neck, or spine.

When a child is born with a large birthmark, or if an older patient is newly evaluated, doctors use specific frameworks to understand the chance that melanocytes (pigment-producing cells) might also be present in the nervous system. This process is called risk stratification, and it helps your care team decide if and when additional tests, like an MRI, are necessary.

How Doctors Classify Birthmarks: The PAS System

Because a baby’s skin grows as they do, doctors don’t just look at the size of the birthmark today. Instead, they use a formula to calculate the Projected Adult Size (PAS) [1]. This estimates how large the mole will be once the individual is fully grown. For adult patients, the actual size is used.

The 2013 Kinsler consensus is the international standard for these categories [1]:

  • Large CMN: A projected adult size between 20 cm and 40 cm (roughly 8 to 16 inches) [2].
  • Giant CMN: A projected adult size greater than 40 cm (over 16 inches) [3].

The larger the PAS, the higher the statistical risk for Neurocutaneous Melanocytosis (NCM) [4][5].

The Three Main Risk Factors

Size is important, but it isn’t the only factor. Your doctor will evaluate three specific “red flags” that increase the likelihood of NCM:

  1. Giant PAS: A birthmark projected to be larger than 40 cm [3].
  2. Satellite Count: The presence of multiple satellite nevi (smaller moles appearing away from the main one). While having 2 or more satellites is a starting point for monitoring, the risk increases significantly with more than 20 satellites at birth [3][6].
  3. Location: Birthmarks located on the head, neck, or posterior midline (the area directly over the spine) are considered higher risk because of their proximity to the central nervous system [7][8].

The Kadonaga and Frieden Diagnostic Criteria

To make a formal diagnosis of NCM, many specialists use a set of rules called the Kadonaga and Frieden criteria [9]. For a diagnosis to be made, a patient typically must meet the following:

  1. Cutaneous (Skin) Findings: The presence of a “large” or “giant” nevus (as defined by PAS) or the presence of three or more smaller congenital nevi [10]. Note: While the criteria allow for a diagnosis with three or more smaller nevi, NCM is statistically much rarer in the absence of a large or giant primary nevus.
  2. Neurological Findings: Evidence of melanosis (benign pigment deposits) or melanoma (cancerous pigment cells) within the brain or spinal cord, usually identified via MRI [11].
  3. Exclusion of Other Causes: There must be no evidence of a primary melanoma in the skin that has spread to the brain [9].

Diagnosis is a tool for preparation; knowing the risk level allows you to build the right team of specialists early on [4].

Common questions in this guide

What is the Projected Adult Size (PAS) for a birthmark?
The Projected Adult Size, or PAS, is a calculation doctors use to estimate how large a baby's birthmark will be when they are fully grown. This measurement helps determine the risk level for neurocutaneous melanocytosis.
Do satellite moles increase the risk of NCM?
Yes, having multiple satellite moles (smaller moles appearing away from the main birthmark) can increase the risk of NCM. The risk becomes significantly higher if a baby is born with more than 20 of these smaller moles.
Why does the location of a large birthmark matter?
Birthmarks located on the head, neck, or directly over the spine are considered higher risk for neurocutaneous melanocytosis. Because these areas are close to the central nervous system, doctors monitor them more closely.
What are the Kadonaga and Frieden criteria?
The Kadonaga and Frieden criteria are medical guidelines used to formally diagnose neurocutaneous melanocytosis. A diagnosis usually requires the presence of a large birthmark and MRI evidence of pigment deposits in the brain or spinal cord, without the presence of skin melanoma.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can we calculate the 'Projected Adult Size' (PAS) today based on the current measurements?
  2. 2.How many satellite nevi do you count, and does this number put the risk level in a higher category for NCM?
  3. 3.Do you use the Kadonaga and Frieden criteria or the 2013 Kinsler consensus for making a formal diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Congenital melanocytic naevi: An up-to-date overview.

    Farabi B, Akay BN, Goldust M, et al.

    The Australasian journal of dermatology 2021; (62(2)):e178-e191 doi:10.1111/ajd.13535.

    PMID: 33591589
  2. 2

    Risk of Malignant Transformation Arising From Giant Congenital Melanocytic Nevi: A 20-year Single-center Study.

    Kim JY, Jeon JH, Choi TH, Kim BJ

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2022; (48(2)):171-175 doi:10.1097/DSS.0000000000003341.

    PMID: 34935754
  3. 3

    Central Nervous System Involvement and Neuroradiological Imaging Insights of Neurocutaneous Melanocytosis in Congenital Melanocytic Nevi.

    Ruff C, Gohla G, Nägele T, Batra M

    Diagnostics (Basel, Switzerland) 2024; (14(21)) doi:10.3390/diagnostics14212345.

    PMID: 39518313
  4. 4

    Congenital melanocytic nevi.

    Moustafa D, Blundell AR, Hawryluk EB

    Current opinion in pediatrics 2020; (32(4)):491-497 doi:10.1097/MOP.0000000000000924.

    PMID: 32692047
  5. 5

    Congenital melanocytic nevi and risk of melanoma.

    Pastore LM, Valentini R, Marghoob AA

    Clinics in dermatology 2025; (43(3)):378-384 doi:10.1016/j.clindermatol.2024.09.004.

    PMID: 39304091
  6. 6

    Melanocytic Nevi in Children: A Review.

    Levy R, Lara-Corrales I

    Pediatric annals 2016; (45(8)):e293-8 doi:10.3928/19382359-20160720-07.

    PMID: 27517357
  7. 7

    Neurocutaneous Melanosis in Association With Large Congenital Melanocytic Nevi in Children: A Report of 2 Cases With Clinical, Radiological, and Pathogenetic Evaluation.

    Chen L, Zhai L, Al-Kzayer LFY, et al.

    Frontiers in neurology 2019; (10()):79 doi:10.3389/fneur.2019.00079.

    PMID: 30792691
  8. 8

    Giant Congenital Melanocytic Nevus Treated With Trametinib.

    Mir A, Agim NG, Kane AA, et al.

    Pediatrics 2019; (143(3)) doi:10.1542/peds.2018-2469.

    PMID: 30792255
  9. 9

    Neurocutaneous melanocytosis presenting in a teenager: A case report and review of the literature.

    Monica I, Kumar LP, Uppin MS, Jagannath Rao Naidu KV

    Journal of cancer research and therapeutics 2015; (11(3)):649 doi:10.4103/0973-1482.138201.

    PMID: 26458618
  10. 10

    Imaging and Clinical Features of Neurocutaneous Melanosis in the Pediatric Population.

    Mormina E, Granata F, Vinci SL, et al.

    Current medical imaging 2021; (17(12)):1391-1402 doi:10.2174/1573405617666210527091109.

    PMID: 34047260
  11. 11

    Malignant Melanoma Arising From a Giant Congenital Melanocytic Nevus in a 3-Year Old: Review of Diagnosis and Management.

    Kugar M, Akhavan A, Ndem I, et al.

    The Journal of craniofacial surgery 2021; (32(4)):e342-e345 doi:10.1097/SCS.0000000000007115.

    PMID: 33170823

This page explains diagnostic criteria and risk factors for neurocutaneous melanocytosis for educational purposes only. Always consult a pediatric dermatologist or neurologist for a formal evaluation of your child's birthmarks.

Get notified when new evidence is published on Neurocutaneous melanocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.